Hillary du
Physician Assistant · Boston, MANPI 1720631492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 407 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- Neurocrine Biosciences, Inc.$809
- Johnson & Johnson$766
- Alkermes, Inc.$751
- plus $3K from 17 others
What the payments were for
- Food & beverage$9,98999%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 99 | $2,261 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,412 |
| Lundbeck LLC | 39 | $1,083 |
| Neurocrine Biosciences, Inc. | 31 | $809 |
| Johnson & Johnson | 29 | $766 |
| Alkermes, Inc. | 30 | $751 |
| Axsome Therapeutics, Inc. | 29 | $500 |
| Teva Pharmaceuticals USA, Inc. | 16 | $424 |
| Otsuka America Pharmaceutical, Inc. | 18 | $409 |
| E.r. Squibb & Sons, L.L.C. | 11 | $404 |
| Vanda Pharmaceuticals Inc. | 14 | $349 |
| Corium, LLC | 12 | $253 |
| Ironshore Pharmaceuticals Inc. | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Indivior Inc. | 4 | $98 |
| Sunovion Pharmaceuticals Inc. | 4 | $90 |
| Supernus Pharmaceuticals, Inc. | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Merck | 2 | $28 |
| Orexo US, Inc. | 1 | $22 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,064 in reported general payments places this provider in the 95th percentile of 3,507 physician assistant providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 125 | $189,302 |
| RexultiBrexpiprazole | 15 | $22,975 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 84 | $14,660 |
| BelsomraSuvorexant | 30 | $13,511 |
| Lurasidone Hcl | 71 | $10,624 |
| Aripiprazole | 78 | $8,801 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 305 | $8,664 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $8,315 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 21 | $5,603 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 92 | $4,629 |
| Clonazepam | 295 | $3,568 |
| Alprazolam | 241 | $3,502 |
| Gabapentin | 174 | $2,941 |
| Quetiapine Fumarate | 174 | $2,849 |
| Hydroxyzine Hcl | 155 | $2,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,261 | $189,302125 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $409 | $22,97515 claims |
| MerckBelsomra | $28 | $13,51130 claims |
| Indivior Inc.Suboxone | $98 | $8,31514 claims |
| Orexo US, Inc.Zubsolv | $22 | $5,60321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,507 physician assistant providers in Massachusetts.
Other physician assistant in Boston
- Andrea MilliganBoston$46K
- Lauren RousseauBoston$42K
- Shari TomasettiBoston$14K
- Tiffany AndradeBoston$12K
- Margaret NaclerioBoston$9K
- Christopher MasseyWilbraham$190K
- Lizabeth O ConnorEverett$182K
- Kimberly ComeauSwampscott$120K
- Stacey PanasciSpringfield$113K
- Jason RandWaltham$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.